Analysts Tell Moderna Investors to Hold After 2024’s Steep Drop
5 days ago · The trend continued throughout the year, despite positive news from the company. Moderna secured a profit of $217 million in the fourth quarter of 2023, beating Wall Street expectations. Then in May, the biotech had its second vaccine approved, mRESVIA, a mRNA shot to protect adults over 60 from respiratory syncytial virus (RSV), with sales ...
Moderna, Inc. (MRNA) Latest Stock News & Headlines - Yahoo …
Get the latest Moderna, Inc. (MRNA) stock news and headlines to help you in your trading and investing decisions.
Moderna R&D day: $1 billion in cost cuts, 10 product launches
Sep 12, 2024 · Moderna on Thursday said it plans to cut around $1.1 billion in expenses by 2027 and win approvals for several new products as it charts a path forward after the rapid decline …
News Details - Moderna
Mar 26, 2024 · mRNA-1283 induced a more robust immune response compared to Spikevax® COVID-19 vaccine, mRNA-1273.222. Next-generation mRNA vaccine design offers the potential of longer shelf life and storage advantages, and paves the way for combination vaccine against influenza and COVID-19, mRNA-1083.
News Details - Moderna
Mar 27, 2024 · Announces next-generation COVID-19 vaccine candidate as fourth respiratory vaccine to successfully meet its Phase 3 endpoints. Expects two more Phase 3 readouts in 2024, including combination vaccine against flu and COVID-19, and vaccine against CMV.
Moderna forecasts lower sales next year, shares near four-year low
Sep 12, 2024 · Moderna pushed back its break-even goal by two years on Thursday as it delayed the timeline for developing several key products and predicted 2025 sales below its forecast for the current year,...
Moderna reports surprise profit on higher-than-expected COVID …
Nov 7, 2024 · Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its COVID-19 vaccine, even with low revenue from its new respiratory...
News Details - Moderna
Jan 8, 2024 · CAMBRIDGE, MA / ACCESSWIRE / January 8, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced business updates and progress on the Company's pipeline of transformative mRNA medicines. Moderna enters 2024 with 45 therapeutic and vaccine programs, nine of which are in late-stage development.
News Details - Moderna
Sep 11, 2023 · Moderna's updated COVID-19 vaccine contains spike proteins for the XBB.1.5 sublineage of SARS-CoV-2 to help prevent COVID-19 in individuals 6 months of age and older. With the U.S. FDA's decision, Moderna will begin shipping doses to vaccination sites across the U.S., with updated vaccines expected to be available in the coming days.
News Details - Moderna
Aug 17, 2023 · With this new trial data, Moderna has now confirmed an antibody response against current strains of concern. Moderna has submitted its updated COVID-19 vaccine to the U.S. Food and Drug Administration, the European Medicines Agency (EMA) and other regulators around the world.